Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 3 | 2019 | 207 | 1.140 |
Why?
|
| Angelman Syndrome | 2 | 2021 | 68 | 0.850 |
Why?
|
| Hippocampus | 5 | 2017 | 824 | 0.840 |
Why?
|
| Fear | 3 | 2017 | 200 | 0.650 |
Why?
|
| rac GTP-Binding Proteins | 2 | 2011 | 26 | 0.640 |
Why?
|
| Stereotyped Behavior | 1 | 2019 | 37 | 0.630 |
Why?
|
| Diet, Ketogenic | 1 | 2019 | 22 | 0.610 |
Why?
|
| Diet Therapy | 1 | 2019 | 41 | 0.610 |
Why?
|
| Fragile X Syndrome | 2 | 2017 | 150 | 0.610 |
Why?
|
| Estradiol | 2 | 2016 | 532 | 0.550 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2016 | 13 | 0.540 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2016 | 34 | 0.530 |
Why?
|
| Motor Activity | 2 | 2019 | 521 | 0.520 |
Why?
|
| Learning | 2 | 2017 | 361 | 0.460 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 203 | 0.450 |
Why?
|
| Epilepsy | 1 | 2021 | 874 | 0.430 |
Why?
|
| Neuropeptides | 1 | 2011 | 113 | 0.350 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2009 | 148 | 0.330 |
Why?
|
| Neuronal Plasticity | 2 | 2011 | 272 | 0.320 |
Why?
|
| Electroencephalography | 3 | 2024 | 865 | 0.320 |
Why?
|
| rac1 GTP-Binding Protein | 3 | 2017 | 66 | 0.320 |
Why?
|
| Association Learning | 1 | 2007 | 21 | 0.270 |
Why?
|
| Avoidance Learning | 1 | 2007 | 58 | 0.260 |
Why?
|
| Nucleus Accumbens | 2 | 2016 | 54 | 0.260 |
Why?
|
| Aminoquinolines | 3 | 2017 | 35 | 0.260 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2019 | 1243 | 0.260 |
Why?
|
| Cyclins | 2 | 2002 | 101 | 0.240 |
Why?
|
| Video Recording | 1 | 2024 | 183 | 0.210 |
Why?
|
| Pyrimidines | 3 | 2017 | 373 | 0.210 |
Why?
|
| Spasms, Infantile | 1 | 2024 | 171 | 0.200 |
Why?
|
| Long-Term Potentiation | 2 | 2017 | 161 | 0.200 |
Why?
|
| Growth Substances | 1 | 2002 | 113 | 0.190 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2002 | 100 | 0.190 |
Why?
|
| Memory | 3 | 2017 | 361 | 0.180 |
Why?
|
| Minocycline | 1 | 2020 | 38 | 0.170 |
Why?
|
| Animals | 11 | 2021 | 34238 | 0.170 |
Why?
|
| Behavior, Animal | 3 | 2019 | 490 | 0.160 |
Why?
|
| Ovariectomy | 2 | 2016 | 183 | 0.160 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2019 | 26 | 0.160 |
Why?
|
| DNA Damage | 1 | 2002 | 513 | 0.160 |
Why?
|
| Fragile X Mental Retardation Protein | 2 | 2017 | 124 | 0.160 |
Why?
|
| Metabolism | 1 | 2019 | 42 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2016 | 94 | 0.150 |
Why?
|
| Rats | 3 | 2021 | 3727 | 0.150 |
Why?
|
| Reflex, Acoustic | 1 | 2017 | 4 | 0.150 |
Why?
|
| Prepulse Inhibition | 1 | 2017 | 4 | 0.150 |
Why?
|
| Reflex, Startle | 1 | 2017 | 32 | 0.140 |
Why?
|
| Theta Rhythm | 1 | 2017 | 26 | 0.140 |
Why?
|
| Dopamine | 1 | 2019 | 282 | 0.140 |
Why?
|
| Conditioning, Operant | 1 | 2016 | 17 | 0.130 |
Why?
|
| Models, Animal | 1 | 2019 | 464 | 0.130 |
Why?
|
| Self Administration | 1 | 2016 | 43 | 0.130 |
Why?
|
| Prostatic Neoplasms | 2 | 2002 | 1547 | 0.130 |
Why?
|
| Endocannabinoids | 1 | 2016 | 37 | 0.130 |
Why?
|
| Behavior, Addictive | 1 | 2016 | 59 | 0.120 |
Why?
|
| Apoptosis | 1 | 2002 | 1806 | 0.120 |
Why?
|
| Dendritic Spines | 2 | 2016 | 60 | 0.120 |
Why?
|
| Pyridines | 1 | 2016 | 230 | 0.120 |
Why?
|
| Phenotype | 2 | 2021 | 4263 | 0.120 |
Why?
|
| Body Weight | 1 | 2019 | 989 | 0.120 |
Why?
|
| Pain | 1 | 2017 | 451 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2016 | 313 | 0.110 |
Why?
|
| Estrogens | 1 | 2016 | 504 | 0.110 |
Why?
|
| Excitatory Postsynaptic Potentials | 2 | 2011 | 130 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2011 | 1020 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2017 | 3744 | 0.090 |
Why?
|
| Pyrones | 1 | 2011 | 5 | 0.090 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2011 | 24 | 0.090 |
Why?
|
| Quinolines | 1 | 2011 | 98 | 0.090 |
Why?
|
| Mice | 7 | 2021 | 17637 | 0.090 |
Why?
|
| Dizocilpine Maleate | 1 | 2009 | 18 | 0.080 |
Why?
|
| Dendrites | 1 | 2011 | 196 | 0.080 |
Why?
|
| Raptors | 1 | 2008 | 5 | 0.080 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2008 | 20 | 0.080 |
Why?
|
| Male | 6 | 2024 | 61524 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2011 | 4405 | 0.070 |
Why?
|
| Synapses | 1 | 2011 | 451 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2008 | 330 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2024 | 16344 | 0.070 |
Why?
|
| Environment | 1 | 2007 | 145 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2002 | 81 | 0.060 |
Why?
|
| Female | 4 | 2024 | 66803 | 0.060 |
Why?
|
| Neurons | 3 | 2011 | 1932 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2002 | 173 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12396 | 0.060 |
Why?
|
| Time Factors | 2 | 2011 | 6336 | 0.050 |
Why?
|
| Humans | 5 | 2024 | 125195 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 4395 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2002 | 40 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 61 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 128 | 0.050 |
Why?
|
| Sleep | 1 | 2024 | 345 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2002 | 723 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2002 | 290 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1064 | 0.040 |
Why?
|
| Child | 1 | 2020 | 24407 | 0.040 |
Why?
|
| Cell Survival | 1 | 2002 | 813 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2002 | 618 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2011 | 4536 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2011 | 982 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 356 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2021 | 789 | 0.040 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2016 | 28 | 0.030 |
Why?
|
| Seizures | 1 | 2021 | 872 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5176 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 208 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 1893 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2016 | 305 | 0.030 |
Why?
|
| Silver Staining | 1 | 2011 | 5 | 0.020 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2011 | 35 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 2523 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 282 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2011 | 326 | 0.020 |
Why?
|
| Infant | 1 | 2024 | 12507 | 0.020 |
Why?
|
| Schizophrenic Psychology | 1 | 2009 | 82 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2008 | 53 | 0.020 |
Why?
|
| Maze Learning | 1 | 2008 | 128 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2008 | 171 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2009 | 311 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 663 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 351 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 429 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2009 | 1017 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 581 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2397 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 1631 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1460 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2002 | 113 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 258 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 211 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2002 | 708 | 0.010 |
Why?
|
| Androgens | 1 | 2002 | 274 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2999 | 0.010 |
Why?
|
| Biopsy | 1 | 2002 | 1237 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2002 | 1276 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 425 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 2064 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 1142 | 0.010 |
Why?
|